Humacyte, Inc. (NASDAQ:HUMA) Given Average Recommendation of "Buy" by Analysts

Key Points

• Humacyte, Inc. has been given a consensus rating of "Buy" by analysts, with six out of eight firms recommending a buy and an average twelve-month price target of $11.71.
• Institutional investors hold 44.71% of the company's stock, with several institutions recently purchasing new stakes valued between $27,000 and $37,000.
• The company's stock opened at $2.40 and has a 52-week range of $1.15 to $9.79, indicating significant volatility.

Shares of Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) have earned an average recommendation of "Buy" from the eight ratings firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $11.7143.

Several brokerages recently commented on HUMA. Benchmark decreased their target price on shares of Humacyte from $17.00 to $14.00 and set a "buy" rating on the stock in a research note on Wednesday, May 14th. HC Wainwright initiated coverage on shares of Humacyte in a research report on Wednesday, May 14th. They issued a "buy" rating and a $4.00 target price on the stock. Wall Street Zen cut shares of Humacyte from a "hold" rating to a "sell" rating in a research note on Friday, July 18th. Finally, D. Boral Capital reiterated a "buy" rating and issued a $25.00 price target on shares of Humacyte in a research note on Wednesday, July 23rd.

Humacyte Trading Down 0.7%

Shares of HUMA traded down $0.02 during mid-day trading on Friday, reaching $2.27. The company's stock had a trading volume of 1,449,146 shares, compared to its average volume of 3,741,242. The stock has a market cap of $351.35 million, a PE ratio of -3.28 and a beta of 1.90. The company has a current ratio of 3.68, a quick ratio of 3.28 and a debt-to-equity ratio of 0.36. Humacyte has a 52 week low of $1.15 and a 52 week high of $8.72. The company's fifty day moving average price is $2.42 and its two-hundred day moving average price is $2.61.

Humacyte (NASDAQ:HUMA - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.10) earnings per share for the quarter, topping analysts' consensus estimates of ($0.19) by $0.09. The business had revenue of $0.52 million during the quarter, compared to the consensus estimate of $0.46 million. On average, analysts predict that Humacyte will post -1.27 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Humacyte

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Columbia Advisory Partners LLC purchased a new stake in Humacyte during the 1st quarter valued at approximately $27,000. Lazari Capital Management Inc. purchased a new stake in Humacyte during the 2nd quarter valued at approximately $27,000. Vanguard Personalized Indexing Management LLC purchased a new stake in Humacyte during the 2nd quarter valued at approximately $30,000. Valeo Financial Advisors LLC purchased a new stake in Humacyte during the 2nd quarter valued at approximately $32,000. Finally, Hamilton Lane Advisors LLC purchased a new stake in Humacyte during the 1st quarter valued at approximately $37,000. 44.71% of the stock is owned by hedge funds and other institutional investors.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.